Literature DB >> 11427215

Preactivated monocytes from hypertensive patients as a factor for atherosclerosis?

Y Dörffel1, S Franz, A Pruss, G Neumann, W Rohde, G R Burmester, J Scholze.   

Abstract

Recently, we reported our findings regarding the elevated secretion patterns of proinflammatory cytokines obtained from peripheral blood monocytes of hypertensive patients. To investigate the direct impact of these preactivated monocytes, the adhesion of monocytes from normal controls and hypertensive patients to vascular endothelial cell monolayers was determined spontaneously and after in vitro stimulation with either lipopolysaccharide (LPS) or angiotensin II (Ang II), with or without preincubation with the AT1 receptor antagonist eprosartan. Peripheral blood monocytes from 20 patients and 20 healthy individuals were isolated by density gradient centrifugation and plastic adherence; endothelial cells were obtained from human umbilical cords by collagenase digestion. The adhesion was determined by an assay with 51Cr-radiolabeled monocytes. Oxygen species release induced by phorbol myristate acetate (PMA) as a further activation marker was analyzed for monocytes and HUVEC by chemiluminescence (CL). Spontaneous adhesion of monocytes from patients and the adhesion after stimulation with Ang II were significantly increased compared with normal controls (P<0.05). Preincubation with eprosartan diminished the adhesion in both groups to comparable levels. In monocytes, peak levels of PMA and Ang II induced CL analysis were significantly higher in patients (P<0.005). These data indicate that preactivated monocytes from hypertensives may be of pathogenic importance in atherosclerosis.

Entities:  

Mesh:

Year:  2001        PMID: 11427215     DOI: 10.1016/s0021-9150(00)00674-2

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

1.  Differential gene expression of bradykinin receptors 1 and 2 in peripheral monocytes from patients with essential hypertension.

Authors:  M E Marketou; J Kontaraki; E Zacharis; F Parthenakis; S Maragkoudakis; I Gavras; H Gavras; P E Vardas
Journal:  J Hum Hypertens       Date:  2014-01-09       Impact factor: 3.012

Review 2.  Understanding the Two Faces of Low-Salt Intake.

Authors:  Branko Braam; Xiaohua Huang; William A Cupples; Shereen M Hamza
Journal:  Curr Hypertens Rep       Date:  2017-06       Impact factor: 5.369

Review 3.  Inflammation in Hypertension.

Authors:  Liang Xiao; David G Harrison
Journal:  Can J Cardiol       Date:  2020-01-24       Impact factor: 5.223

4.  Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis.

Authors:  Suguru Yamamoto; Patricia G Yancey; Yiqin Zuo; Li-Jun Ma; Ryohei Kaseda; Agnes B Fogo; Iekuni Ichikawa; MacRae F Linton; Sergio Fazio; Valentina Kon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-10-06       Impact factor: 8.311

Review 5.  Atherosclerosis in chronic kidney disease: the role of macrophages.

Authors:  Valentina Kon; MacRae F Linton; Sergio Fazio
Journal:  Nat Rev Nephrol       Date:  2010-11-23       Impact factor: 28.314

6.  Norepinephrine increases NADPH oxidase-derived superoxide in human peripheral blood mononuclear cells via α-adrenergic receptors.

Authors:  Shekhar H Deo; Nathan T Jenkins; Jaume Padilla; Alan R Parrish; Paul J Fadel
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-09-25       Impact factor: 3.619

7.  Human monocyte transcriptional profiling identifies IL-18 receptor accessory protein and lactoferrin as novel immune targets in hypertension.

Authors:  Matthew R Alexander; Allison E Norlander; Fernando Elijovich; Ravi V Atreya; Amadou Gaye; Juan S Gnecco; Cheryl L Laffer; Cristi L Galindo; Meena S Madhur
Journal:  Br J Pharmacol       Date:  2018-06-21       Impact factor: 8.739

Review 8.  Emerging Role of the Inflammasome and Pyroptosis in Hypertension.

Authors:  Carmen De Miguel; Pablo Pelegrín; Alberto Baroja-Mazo; Santiago Cuevas
Journal:  Int J Mol Sci       Date:  2021-01-21       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.